Menez S, Moledina DG, Thiessen-Philbrook H, et al. - Via this prospective cohort study, researchers examined if and how urinary biomarkers associate with adverse kidney outcomes among patients hospitalized with COVID-19.

• Among 153 patients who were hospitalized with COVID-19 at 2 academic medical centers, researchers assessed composite of KDIGO stage 3 AKI, requirement for dialysis, or death within 60 days of hospital admission.

• Various kidney biomarker levels were compared between the setting of COVID-19 vs other common AKI settings.

• The highest risk of sustaining primary composite outcome was observed in correlation with two-fold higher levels of neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein, and kidney injury molecule-1.

• There appeared a lower risk of the primary outcome in correlation with higher epidermal growth factor levels.

• Overall findings suggest that in patients hospitalized with COVID-19, urinary biomarkers are linked with adverse kidney outcomes and may yield relevant information to monitor kidney disease progression and recovery.